The Center for AIDS Information & Advocacy
The CFA advocates both locally and nationally for better treatments and better access to care for persons living with HIV/AIDS and strives to keep the Houston medical and affected community informed, updated, and involved in the search for a cure. The CFA also publishes Research Initiative/Treatment Action! (RI_TA!_). This quarterly journal provides the latest HIV/AIDS information to the medical and HIV communities.
Research Initiative/Treatment Action (RI_TA!) is a publication of The Center for AIDS (CFA). RI_TA! covers issues in HIV research and policy, and is intended for the HIV medical, research, and professional communities. The statements and opinions expressed herein do not imply recommendations or endorsement. Always consult your doctor before altering a prescribed drug regimen or taking any drug or supplement.
RI_TA!_ is available in print or online, and is currently produced four times a year. The printed publication is free of charge for people with HIV/AIDS, the agencies that serve the HIV/AIDS infected and affected population, and research and educational institutions. It is available in print at The CFA information center and by mail.
RI_TA!_ is distributed widely in the U.S. and sent to more than a dozen countries. The publication is indexed by the National Library of Medicine in PubMed and is included in several other free and commercial databases.
Letters to the editor, pertaining to material published in RI_TA!_, are encouraged and may be sent to email@example.com. Letters will be published at the editor's discretion, and may be modified or edited as deemed necessary or appropriate.
If you would like RI_TA!_ sent to you or your organization, please contact The CFA with your full mailing address. Bulk mailings are not available for RI_TA!_ (single copies only) unless the recipient pays for shipping and handling (contact The CFA for details). Although the publication is free, donations are always appreciated to help with publication and shipping costs.
How to Reach the Center for AIDS
P.O. Box 66306
Houston, TX 77266-6306
Houston, TX 77006
Toll Free: 888.341.1788
Latest by The Center for AIDS Information & Advocacy
Quitting smoking can certainly be a tough commitment to make. For HIV-positive smokers who may be struggling to quit, here are 10 things to know.
How can people with HIV prevent and manage diabetes? This guide can help.
Chlamydia infection often has no physical signs or symptoms, so you may not know you're infected unless you get tested regularly. Sexually active men with HIV should be tested for chlamydia every 3 to 6 months, and sexually active women should be...
Syphilis is a growing threat to gay and bisexual men with and without HIV. Syphilis rates have also climbed recently in women with and without HIV. Syphilis can spread through anal, vaginal, or oral sex. Oral sex is not "safe sex" when it comes t...
Table of Contents
Introduction 25 Things You Need to Do if You Have HIV
If you have HIV, start care as soon as possible with a health care provider or medical group that has HIV experience. With your HIV provider's help, decide when to ...
Epivir tablets are film-coated, white, and diamond-shaped with the dosage "150" imprinted on one side and "GX CJ7" on the other side. This drug is also available in a flavored solution.
Background and Description Coformulations Dose Food Restr...
Viread is supplied in 300-mg tablets that are almond shaped, light blue film coated, and embossed with "GILEAD" and "4331" on one side and with "300" on the other side.
Background Coformulations Dose Food Restrictions Storage Patient Assis...
Emtriva capsules are half light blue and half white. The light-blue half shows the dose (200 mg) and the white half says "Gilead" with the Gilead corporate logo on the left. There is also an oral solution available for Emtriva.
Background and Descri...
Norvir soft-gelatin capsules are white and imprinted with the Abbott corporate logo on one side. Norvir is also available in a liquid formulation.
Background and Description Dose Food Restrictions Storage Patient Assistance Side Effects an...
Zidovudine is supplied most commonly in film-coated tablets (300 mg, biconvex, round and white) with "GXCW3" on one side and "300" on the other. The drug also comes in capsules (100 mg), flavored syrup, and an intravenous infusion. Dosing may vary.